Online citations, reference lists, and bibliographies.
← Back to Search

An Unusually Large Pleural Mesothelioma With An Outstanding Clinical Response And Long Lasting Survival: A Case Report And Literature Review

N. Zilembo, M. Vitali, F. Pietrantonio, M. Platania, M. Del Vecchio, E. Bajetta
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma is a neoplasm characterized by an increasing incidence and poor prognosis. When surgical treatment cannot be performed, systemic chemotherapy remains the main therapeutic option. Here we report the case of a 41-year-old female patient with epithelioid malignant pleural mesothelioma who was treated with carboplatin and pemetrexed despite her critical condition. She showed an impressive response to this first-line chemotherapy and, after disease progression, to further chemotherapy with gemcitabine and vinorelbine. She is still alive, with unexpectedly long-lasting survival. Free full text available at www.tumorionline.it
This paper references
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1200/JCO.2007.25.18_SUPPL.7526
Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)
T. Karrison (2007)
10.1097/01.JTO.0000283221.63767.BA
C5-06: Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients with malignant mesothelioma
H. Kindler (2007)
Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
K. Pietras (2002)
10.1158/1078-0432.CCR-07-0883
Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors
Y. Ali (2007)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1016/j.lungcan.2008.04.001
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
10.1016/S1556-0864(15)31509-4
Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma
D. P. M. van den Bogaert (2006)
10.1177/107327480601300402
Malignant pleural mesothelioma: a comprehensive review.
R. Ismail-Khan (2006)
10.1016/S0169-5002(01)00257-4
Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.
G. Ceresoli (2001)
10.1002/cncr.23337
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1080/00015458.2010.11680561
Palliative Treatment of Malignant Pleural Effusions
D. Horn (2010)
10.1038/sj.bjc.6604442
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. Ceresoli (2008)
10.1016/j.ejcts.2007.09.044
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
P. Borasio (2008)
10.1002/cncr.23617
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
D. Jackman (2008)
Poplin EA: Phase I and pharmacokinetic study of imatinib mesylate (Gleevec®) and gemcitabine in patients with refractory solid tumors
Y Ali (2007)
10.6004/JNCCN.2012.0006
[Malignant pleural mesothelioma].
Q. Kong (1983)
Mesothe - lioma review
AS Tsao



Semantic Scholar Logo Some data provided by SemanticScholar